Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study.

TitleAdipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study.
Publication TypeJournal Article
Year of Publication2012
AuthorsMarques-Vidal, P, Schmid, R, Bochud, M, Bastardot, F, von Kanel, R, Paccaud, F, Glaus, J, Preisig, M, Waeber, G, Vollenweider, P
JournalPLoS One
Volume7
Issue12
Paginatione51768
Date Published2012
DOI10.1371/journal.pone.0051768
ISSN1932-6203
KeywordsAdipokines, Adult, Aged, Biomarkers, Diabetes Mellitus, Type 2, Female, Humans, Incidence, Inflammation, Liver, Male, Middle Aged, Risk Factors, Switzerland
Abstract

CONTEXT: There is contradictory information regarding the prognostic importance of adipocytokines, hepatic and inflammatory biomarkers on the incidence of type 2 diabetes. The objective was to assess the prognostic relevance of adipocytokine and inflammatory markers (C-reactive protein - CRP; interleukin-1beta - IL-1β; interleukin-6- IL-6; tumour necrosis factor-α - TNF-α; leptin and adiponectin) and gamma-glutamyl transpeptidase (γGT) on the incidence of type 2 diabetes.

METHODS: Prospective, population-based study including 3,842 non-diabetic participants (43.3% men, age range 35 to 75 years), followed for an average of 5.5 years (2003-2008). The endpoint was the occurrence of type 2 diabetes.

RESULTS: 208 participants (5.4%, 66 women) developed type 2 diabetes during follow-up. On univariate analysis, participants who developed type 2 diabetes had significantly higher baseline levels of IL-6, CRP, leptin and γGT, and lower levels of adiponectin than participants who remained free of type 2 diabetes. After adjusting for a validated type 2 diabetes risk score, only the associations with adiponectin: Odds Ratio and (95% confidence interval): 0.97 (0.64-1.47), 0.84 (0.55-1.30) and 0.64 (0.40-1.03) for the second, third and forth gender-specific quartiles respectively, remained significant (P-value for trend = 0.05). Adding each marker to a validated type 2 diabetes risk score (including age, family history of type 2 diabetes, height, waist circumference, resting heart rate, presence of hypertension, HDL cholesterol, triglycerides, fasting glucose and serum uric acid) did not improve the area under the ROC or the net reclassification index; similar findings were obtained when the markers were combined, when the markers were used as continuous (log-transformed) variables or when gender-specific quartiles were used.

CONCLUSION: Decreased adiponectin levels are associated with an increased risk for incident type 2 diabetes, but they seem to add little information regarding the risk of developing type 2 diabetes to a validated risk score.

Notes

Publication types: Journal ArticlePublication Status: ppublish

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/23251619?dopt=Abstract

Alternate JournalPLoS ONE
Citation Key / SERVAL ID3364
PubMed ID23251619
PubMed Central IDPMC3520903
Projets de recherche et mandats IUMSP: 

                         

IUMSP | www.iumsp.ch
Institute of Social and Preventive Medicine
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top